Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.

Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.

Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.

Abstract: The disclosure concerns a method for patient stratification and selection of patients who are candidates for a specific therapy is described which is based on quantifying one or more digital image analysis feature distributions from stained tissue. The method extends beyond the abilities of a manual observer and a microscope, and generally comprises: acquiring digital images of stained tissue sections from patients submitted for evaluation, applying an algorithm process to said images with a computer to extract the morphometric and staining features of image pixels and tissue objects, deriving one or more distribution function for one or more image analysis features, calculating a summary statistic of the one or more distribution functions, and using said summary statistic along with an associated predefined patient stratification paradigm to separate a patient cohort into distinct strata which correspond to a decision to include or exclude a patient for a specific therapy.

Abstract: The disclosure concerns a method for patient stratification and selection of patients who are candidates for a specific therapy is described which is based on quantifying one or more digital image analysis feature distributions from stained tissue. The method extends beyond the abilities of a manual observer and a microscope, and generally comprises: acquiring digital images of stained tissue sections from patients submitted for evaluation, applying an algorithm process to said images with a computer to extract the morphometric and staining features of image pixels and tissue objects, deriving one or more distribution function for one or more image analysis features, calculating a summary statistic of the one or more distribution functions, and using said summary statistic along with an associated predefined patient stratification paradigm to separate a patient cohort into distinct strata which correspond to a decision to include or exclude a patient for a specific therapy.

Abstract: Provided are methods for characterizing microvesicles or other membranous structures. The methods involve assaying samples for microvesicles or other membranous structures, and include in certain aspects determining the presence or absence of tissue transglutaminase (tTG) and/or cross-linked fibronection (FN). The microvesicles or other membranous structures can be separated from a sample using recombinant tTG or a derivative of it, or tTG or FN binding partners. Also provided are methods for inhibiting the transfer of cargo from microvesicles which contain tTG to one or more cells. This involves administering to the individual a tTG inhibitor, such as a cell-impermeable tTG inhibitor. Also provided are compositions which contain a population of microvesicles or other membranous structures, where the population is attached to tTG or a derivative thereof, or to tTG or an FN binding partner. Kits which contain reagents and other components for carrying out the method are also provided.

Abstract: A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed.

Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.